ERBB2 and breast carcinoma: For example, a patient with a grade 1, ER positive, progesterone receptor-positive, HER2-negative breast cancer has a 10-year ROR of approximately 10% to 15%; adjuvant endocrine therapy would reduce this risk by approximately one-third to one-half.